AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9759414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral lidocaine 1%
Number of subjects: 80
Study 9759414 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 80
Study 7836518 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mM pentoxifylline
Number of subjects: 20
Study 7836518 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of pentoxifylline)
Number of subjects: 20
Study 3403422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air inhalation (3.6 degrees C)
Number of subjects: 8
Study 3403422 — intervention group
Group type: COMPARATOR
Intervention: Hot air inhalation (ambient air)
Number of subjects: 8
Study 30175556 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal complex Soratinex® (Dr Michaels®) applied twice daily for 8 weeks
Number of subjects: 0
Study 29178815 — intervention group
Group type: EXPERIMENTAL
Intervention: Core laboratory interpretation of coronary CT angiography
Number of subjects: 4347
Study 29178815 — intervention group
Group type: COMPARATOR
Intervention: Site interpretation of coronary CT angiography
Number of subjects: 4347
Study 29178815 — intervention group
Group type: EXPERIMENTAL
Intervention: Core laboratory interpretation
Number of subjects: 4347
Study 29178815 — intervention group
Group type: COMPARATOR
Intervention: Site interpretation
Number of subjects: 4347
Study 29178815 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 4347
Study 28271733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 0
Study 28271733 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glulisine (IG) once daily (QD)
Number of subjects: 0
Study 28271733 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glulisine (IG) three times daily (TID)
Number of subjects: 0
Study 25343729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulberry leaf aqueous extract (MLAE) supplementation (5g/day)
Number of subjects: 36
Study 25343729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23238645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 23238645 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 80
Study 21574739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure inducing distraction (performance-contingent outcomes)
Number of subjects: 0
Study 21574739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure inducing explicit monitoring (monitoring by others)
Number of subjects: 0
Study 21574739 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions designed to eliminate choking
Number of subjects: 0
Study 21574739 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring-pressure in a procedural-based task (serial reaction time task)
Number of subjects: 0
Study 18076740 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent retractable extension device (TRE)
Number of subjects: 895
Study 18076740 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy without TRE
Number of subjects: 895
Study 18076740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hood-assisted colonoscopy
Number of subjects: 895
Study 18076740 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy without hood
Number of subjects: 895
Study 16931220 — intervention group
Group type: EXPERIMENTAL
Intervention: ANDY-Disc
Number of subjects: 270
Study 16931220 — intervention group
Group type: COMPARATOR
Intervention: UltraBag
Number of subjects: 270
Study 12649711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg once daily for 5 days
Number of subjects: 414
Study 12649711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily for 5 days
Number of subjects: 414
Study 12649711 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg amoxicillin/125 mg clavulanic acid t.i.d. for 10 days
Number of subjects: 414
Study 12649711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg
Number of subjects: 414
Study 12649711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 414
Study 12649711 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 414
Study 10880892 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 41
Study 10880892 — intervention group
Group type: COMPARATOR
Intervention: Insuman (I)
Number of subjects: 41
Study 9366821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen (norgestimate/ethinyl estradiol)
Number of subjects: 257
Study 9366821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 1287139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (oral administration)
Number of subjects: 20
Study 1287139 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam-ampicillin (parenteral administration)
Number of subjects: 20
Study 6489742 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive psychosocial intervention (N = 59), techniques to lower distress and improve coping over four weeks.
Number of subjects: 381
Study 6489742 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 58), received no intervention.
Number of subjects: 381
Study 31695482 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aromatherapy with peppermint essence
Number of subjects: 80
Study 31695482 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 80
Study 30400937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) 100 mg/d, prescribed at night, starting from early pregnancy (12-20 weeks of gestation) until 34 weeks of gestation.
Number of subjects: 1000
Study 30400937 — intervention group
Group type: COMPARATOR
Intervention: Routine examinations (control group).
Number of subjects: 1000
Study 27509102 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat
Number of subjects: 67
Study 27509102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23790018 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 72
Study 23790018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20484899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein apheresis (LA)
Number of subjects: 15
Study 20484899 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 15
Study 20484899 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 16367988 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 0.6 mg/kg/day)
Number of subjects: 25
Study 16367988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11481263 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 94
Study 11481263 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT)
Number of subjects: 94
Study 11481263 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry (SLP)
Number of subjects: 94
Study 11481263 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Wavelength Automated Perimetry (SWAP)
Number of subjects: 94
Study 9725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 20 mg
Number of subjects: 33
Study 9725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg, 10 mg, 20 mg)
Number of subjects: 33
Study 9725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 33
Study 9725543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7527325 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0
Study 7527325 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet and zidovudine
Number of subjects: 0
Study 7527325 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 0
Study 2567714 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily FSH therapy
Number of subjects: 12
Study 2567714 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day FSH therapy
Number of subjects: 12
Study 4156819 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (X) diet
Number of subjects: 125
Study 4156819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (F) diet
Number of subjects: 125
Study 4156819 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (S) diet
Number of subjects: 125
Study 30222768 — intervention group
Group type: EXPERIMENTAL
Intervention: Link4Health strategy (including point-of-care CD4+ count testing, accelerated ART initiation, mobile phone appointment reminders, care and prevention package, non-cash financial incentive)
Number of subjects: 0
Study 30222768 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 27427284 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based decisions with large samples taken
Number of subjects: 0
Study 27427284 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based decisions with few samples taken
Number of subjects: 0
Study 27427284 — intervention group
Group type: EXPERIMENTAL
Intervention: Description-based decisions
Number of subjects: 0
Study 25326742 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 83
Study 25326742 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 83
Study 22706091 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc prosthesis surgery
Number of subjects: 116
Study 22706091 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 116
Study 20433807 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit vaccine
Number of subjects: 0
Study 20433807 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted subunit vaccine
Number of subjects: 0
Study 18310480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 289
Study 18310480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol
Number of subjects: 289
Study 18310480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 15671109 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg ENG daily and 400 mg TD every 4 weeks for 48 weeks
Number of subjects: 112
Study 15671109 — intervention group
Group type: COMPARATOR
Intervention: 300 microg ENG daily and 400 mg TD every 6 weeks for 48 weeks
Number of subjects: 112
Study 12621386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cisapride (0.07 mg/kg)
Number of subjects: 17
Study 12621386 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (0.025 mg/kg)
Number of subjects: 17
Study 12621386 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.15 mg/kg)
Number of subjects: 17
Study 10533454 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms/kg of granisetron
Number of subjects: 49
Study 10533454 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg of granisetron
Number of subjects: 49
Study 10533454 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms/kg and 40 micrograms/kg of granisetron
Number of subjects: 49
Study 8901154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐gluc (2 x 50 mg Fe per day, per os) plus MAH (2 x 7.5 mmol Mg per day, p.o.)
Number of subjects: 2
Study 8901154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐gluc plus MAH
Number of subjects: 2
Study 8901154 — intervention group
Group type: COMPARATOR
Intervention: Fe‐gluc alone
Number of subjects: 2
Study 1651211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 243
Study 1651211 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplement administration
Number of subjects: 243
Study 1651211 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated control group
Number of subjects: 243
Study 1651211 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 243
Study 6616987 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (0.1 mg/kg i.v., followed by an infusion of 0.01 mg/kg/min)
Number of subjects: 14
Study 6616987 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipin (20 mg sublingually)
Number of subjects: 14
Study 6616987 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem (0.2 mg/kg i.v., followed by infusion of 0.02 mg/kg/min)
Number of subjects: 14
Study 31280789 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-screening tool and referral pathway pamphlet intervention
Number of subjects: 70
Study 31280789 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 70
Study 29777665 — intervention group
Group type: EXPERIMENTAL
Intervention: S2S intervention group (text messages about sexual health)
Number of subjects: 88
Study 29777665 — intervention group
Group type: COMPARATOR
Intervention: Control group (text messages about diet and/or exercise)
Number of subjects: 88
Study 27502480 — intervention group
Group type: EXPERIMENTAL
Intervention: MAKINGtheLINK intervention group
Number of subjects: 22
Study 27502480 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 22
Study 24500418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (200 mg/m² orally every 12 hours)
Number of subjects: 62
Study 24500418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22180622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose regimen of intravenous artesunate (given at 0, 24, and 48 hours)
Number of subjects: 171
Study 22180622 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5-dose regimen of intravenous artesunate (given at 0, 12, 24, 48, and 72 hours)
Number of subjects: 171
Study 22180622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose regimen of intravenous artesunate
Number of subjects: 171
Study 22180622 — intervention group
Group type: COMPARATOR
Intervention: 5-dose regimen of intravenous artesunate
Number of subjects: 171
Study 20451215 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 (25 μg)
Number of subjects: 20
Study 20451215 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 (50 μg)
Number of subjects: 20
Study 20451215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20451215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after CCK-4)
Number of subjects: 20
Study 17333157 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AT (sulfadoxine/pyrimethamine + artesunate)
Number of subjects: 16
Study 17333157 — intervention group
Group type: COMPARATOR
Intervention: SP (sulfadoxine/pyrimethamine)
Number of subjects: 16
Study 16351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity denial experiences
Number of subjects: 0
Study 16351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception of American identity
Number of subjects: 0
Study 16351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily experiences of identity denial
Number of subjects: 0
Study 16351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactions to identity denial
Number of subjects: 0
Study 12063480 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U BTX‐A (BOTOX, Allergan, Inc) injected intramuscularly into 5 glabellar sites
Number of subjects: 264
Study 12063480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 10223776 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 14
Study 10223776 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study 8536898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic, low osmolarity contrast media
Number of subjects: 1659
Study 8536898 — intervention group
Group type: COMPARATOR
Intervention: Standard ionic contrast media
Number of subjects: 1659
Study 8536898 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic ERCP
Number of subjects: 1659
Study 8536898 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic procedures
Number of subjects: 1659
Study 8536898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter of Oddi manometry
Number of subjects: 1659
Study 2244556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day)
Number of subjects: 93
Study 2244556 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin followed by warfarin
Number of subjects: 93
Study 2244556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (80 mg/day) plus heparin and then warfarin
Number of subjects: 93
Study 14039 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylpyraline (Lergobine)
Number of subjects: 63
Study 14039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31739434 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (8 mg per day/40 mg total for 5 days)
Number of subjects: 90
Study 31739434 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine aescinate (5 mL for group 2 and 10 mL for group 3)
Number of subjects: 90
Study 31739434 — intervention group
Group type: COMPARATOR
Intervention: Baseline therapy with lornoxicam (16 mg per day)
Number of subjects: 90
Study 28627217 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar electrical stimulation therapy (IG: n = 17)
Number of subjects: 28
Study 28627217 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG: n = 11)
Number of subjects: 28
Study 26694436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based lifestyle intervention
Number of subjects: 589
Study 26694436 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 589
Study 24263023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 100
Study 24263023 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 100
Study 24263023 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 24263023 — intervention group
Group type: COMPARATOR
Intervention: Non-transplanted hearts
Number of subjects: 100
Study 21802332 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (glargine or NPH)
Number of subjects: 34
Study 21802332 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump
Number of subjects: 34
Study 21802332 — intervention group
Group type: COMPARATOR
Intervention: Guardian(®) CGMS
Number of subjects: 34
Study 21802332 — intervention group
Group type: COMPARATOR
Intervention: Capillary glucose monitoring (SMBG)
Number of subjects: 34
Study 21802332 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of below-target IG with 10 g of sucrose
Number of subjects: 34
Study 21802332 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of above-target IG
Number of subjects: 34
Study 19463514 — intervention group
Group type: EXPERIMENTAL
Intervention: Catania stent with Polyzene-F
Number of subjects: 55
Study 19463514 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study 16397290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aspirin, 3 times daily for 6 days
Number of subjects: 10
Study 15132025 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning intervention
Number of subjects: 118
Study 15132025 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation control
Number of subjects: 118
Study 11269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive repair (Group 1)
Number of subjects: 34
Study 11269980 — intervention group
Group type: COMPARATOR
Intervention: Conventional repairs (Group 2)
Number of subjects: 34
Study 9306741 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair Evaluation Checklist (14 items) used by secretaries
Number of subjects: 57
Study 9306741 — intervention group
Group type: COMPARATOR
Intervention: Chair design
Number of subjects: 57
Study 9306741 — intervention group
Group type: COMPARATOR
Intervention: Chair preference assessment
Number of subjects: 57
Study 9612038 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpastes containing NaF
Number of subjects: 25
Study 9612038 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpastes containing Na2PO3F
Number of subjects: 25
Study 9612038 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste with no fluorine
Number of subjects: 25
Study 3331264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of prostacyclin
Number of subjects: 9
Study 3331264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (solvent) infusions
Number of subjects: 9
Study 31695348 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication regimen complexity (MRCI) and number of daily administration times
Number of subjects: 242
Study 31695348 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 242
Study 31695348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia severity
Number of subjects: 242
Study 29374589 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational GBS vaccine composed of capsular polysaccharides Ia, Ib, and III conjugated to genetically detoxified Diphtheria toxin CRM197
Number of subjects: 0
Study 29374589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29374589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord sera from vaccine recipients
Number of subjects: 0
Study 27443451 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg/day
Number of subjects: 1753
Study 27443451 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 2000 mg/day
Number of subjects: 1753
Study 27443451 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily treatment of valaciclovir
Number of subjects: 1753
Study 27443451 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1753
Study 24355050 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene from dietary supplements
Number of subjects: 0
Study 24355050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C from dietary supplements
Number of subjects: 0
Study 24355050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E from dietary supplements
Number of subjects: 0